Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Aspirin Continuation, Aspirin Discontinuation.
- Кому может быть актуально
- Состояния в реестре: Chronic Subdural Hematoma. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Китай
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Safety and Efficacy of Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma: A Randomized Clinical Trial
Обзор
This clinical study aims to learn about the efficacy and safety of aspirin continuation or discontinuation in conservative treatment for chronic subdural hematoma. All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to either continue or discontinue aspirin administration. By participating in this study, participants can receive additional scientific guidance on aspirin medication management beyond routine conservative treatment, thereby optimizing individualized therapy.
Подробное описание
Chronic subdural hematoma is a common condition in neurosurgery, predominantly affecting the elderly. Its incidence increases with age, often developing gradually following minor head trauma. Clinical manifestations vary widely, with severe cases potentially leading to coma or even death, imposing a significant burden on patients and their families.
Current treatment approaches for chronic subdural hematoma include surgical intervention and conservative management. Conservative treatment is suitable for some patients with milder conditions or high surgical risk, primarily involving bed rest and medication. However, its efficacy varies among individuals, and close monitoring for multiple potential complications is essential throughout the treatment process.
Aspirin, a commonly used antiplatelet agent, is widely applied in the prevention and treatment of cardiovascular and cerebrovascular diseases. Its use in chronic subdural hematoma patients presents complexities: some patients had been taking aspirin long-term prior to onset. Whether to continue aspirin during conservative management remains controversial, necessitating further research to clarify its safety and efficacy. Continuing the medication may increase the risk of hematoma enlargement, while discontinuation may trigger thromboembolic events.
For cSDH patients on long-term aspirin therapy who opt for conservative management, there is currently no guideline or consensus on "continue vs. discontinue." Clinical decisions are often made by multidisciplinary teams (MDTs) based on individualized risk assessment of bleeding versus thrombosis (with a higher rate of discontinuation strategies). A randomized controlled trial in surgical patients (JAMA Neurology, 2025) showed that discontinuing aspirin after surgery did not reduce 6-month recurrence, and discontinuation-related complications showed no significant difference, suggesting that a "one-size-fits-all" discontinuation approach is unreasonable. However, this evidence cannot be extrapolated to the conservative treatment population, making the conduct of this RCT practically necessary.
Вмешательства
- Препарат Aspirin Continuation
All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to continue aspirin administration. This group of participants received oral administration of aspirin at a dose of 100 mg per day. - Препарат Aspirin Discontinuation
All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to discontinue aspirin administration. This group of participants did not use aspirin during the treatment period.
Первичные конечные точки
- recurrence or progression of the subdural hematoma [Срок оценки: 6 months]
Вторичные конечные точки (11)
- modified Rankin Score (mRS) [Срок оценки: at 6 months]
- Surgical conversion rate [Срок оценки: at 6 months]
- mortality [Срок оценки: at 6 months]
- Peripheral vascular events [Срок оценки: 6 months]
- Acute cardiovascular and cerebrovascular events [Срок оценки: 6 months]
- new-onset contralateral chronic subdural hematoma [Срок оценки: 6 months]
- Change in hematoma volume [Срок оценки: 6 months]
- EQ-5D-5L Questionnaire [Срок оценки: 6 months]
- Montreal Cognitive Assessment Scale [Срок оценки: 6 months]
- Red Blood Cell Lifespan [Срок оценки: 6 months]
- Other adverse events [Срок оценки: 6 months]
Критерии участия
Критерии включения
- Age ≥18 years, male or female;
- Confirmed diagnosis of chronic subdural hematoma (cSDH) by cranial CT and/or MRI;
- Intended for conservative management (i.e., no surgical evacuation indication at enrollment);
- Regular aspirin use at enrollment;
- Informed consent signed by the patient or legal representative.
Критерии исключения
- Patients requiring emergency surgery to remove hematoma at enrollment;
- Concurrent use of other anticoagulants or antiplatelet agents that cannot be discontinued according to the study protocol;
- cSDH secondary to other diseases or conditions (e.g., excessive drainage from ventriculoperitoneal shunts, intracranial tumors);
- Active bleeding events or major cardiac events (e.g., acute myocardial infarction, unstable angina, or revascularization surgery) within 30 days prior to enrollment;
- Known bleeding disorders (e.g., hemophilia, severe thrombocytopenia);
- Individuals unable to provide informed consent or for whom completion of follow-up is anticipated to be difficult.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Простое слепое
- Основная цель
- Лечение
Центры проведения
Китай · 2 центра
- Xuanwu Hospital Capital Medical University — Пекин
- Tianjin Medical University General Hospital — Тяньцзинь
Идентификаторы
NCT: NCT07240454 · Aspirin CSDH